Tag: aasld

October 17, 2017

VBI Vaccines Hepatitis B Data Selected as Presidential Poster of Distinction

VBI Vaccines announced a company's abstract has been selected as a "Presidential Poster of Distinction" for presentation at the annual...
November 15, 2016

Enanta Pharmaceuticals Announces AbbVie’s Investigational Regimen of Glecaprevir/Pibrentasvir Shows High SVR Rates

Enanta Pharmaceuticals today announced 98 percent of chronic hepatitis C virus infected patients with severe chronic kidney disease achieved sustained...
October 3, 2016

Enanta Pharmaceuticals Announces New Data Presentations at the AASLD Liver Meeting

Enanta Pharmaceuticals, a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases,...
October 1, 2016

Arbutus to Present HBV Data at the 2016 AASLD Liver Meeting

Arbutus Biopharma, an industry-leading hepatitis B virus therapeutic solutions company, today announced presentation of data at the 2016 American Association...
September 9, 2016

Achillion Announces Results of Janssen’s Phase 2a Trial

Achillion Pharmaceuticals announced today that new interim results from a phase 2a study being conducted by Alios BioPharma, part of...
April 14, 2016

New Analyses of the Phase 3 POISE Trial of Ocaliva™ (Obeticholic Acid) for the Treatment of PBC Presented at EASL

NEW YORK, April 14, 2016 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the...